A Phase 2 interventional study of lisocabtagene maraleucel in Lymphoma, Non-Hodgkin, Lymphoma and Lymphoma, B-Cell, sponsored by Juno Therapeutics, a Subsidiary of Celgene. Completed at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-27.
Sponsored by Juno Therapeutics, a Subsidiary of Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb — none open to participants now, 1 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · Bristol-Myers Squibb.
Among the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb, this one is the 10th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2018, is one of 6 in phase 2, and was the 18th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →None of the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 11 · Phase 3 2
First in 2007; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 104 across the 19 interventional studies, 20 across the 2 observational. Of the 20 that completed or were terminated, 11 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Juno Therapeutics, a Subsidiary of Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Juno Therapeutics, a Subsidiary of Celgene is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
1 of the studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05688475Bristol-Myers SquibbA Rollover Study of CC-122 | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are refractory to, two lines of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting. Subjects will receive treatment with JCAR017 and will be followed for up to 2 years.
This is an open-label, multicenter, Phase 2 study to assess the safety and antitumor activity in adult patients with relapsed or refractory B-cell non-Hodgkin Lymphoma when administered with lisocabtagene maraleucel (JCAR017) in the outpatient setting.
Upon the successful product generation of lisocabtagene maraleucel, subjects will enter the treatment phase of the study. Treatment will include lymphodepleting chemotherapy followed by lisocabtagene maraleucel administration. Subjects will then enter the post-treatment follow-up phase of the study and will be followed for approximately 24 months for safety, disease status, health-related quality of life (HRQoL), and survival. Long-term follow-up will continue under a separate long-term follow-up protocol, per health regulatory authority guidelines, currently up to 15 years after the last lisocabtagene maraleucel administration.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
This study's enrollment of 104 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Browse Lymphoma, Large B-Cell, Diffuse studies →Juno Therapeutics, a Subsidiary of Celgene is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
First submitted before Juno Therapeutics, Inc. became part of Bristol-Myers Squibb.
Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of lisocabtagene maraleucel. During lisocabtagene maraleucel production, subjects may receive low-dose chemotherapy for disease control. Upon successful generation of lisocabtagene maraleucel product, subjects will receive treatment which will include lymphodepleting chemotherapy followed by one dose of lisocabtagene maraleucel administered by intravenous (IV) injection.
Biological: lisocabtagene maraleucel
lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection
Also known as: JCAR017, liso-cel
Percentage of Participants With Cytokine Release Syndrome (CRS) Adverse Events Grade ≥ 3
Cytokine release syndrome is characterized by high fever, fatigue, nausea, headache, dyspnea, tachycardia, rigors, hypotension, hypoxia, myalgia/arthralgia, and anorexia. Incidence of Grade ≥ 3 CRS, based on the TEAE with MedDRA PT "Cytokine release syndrome," graded according to the grading scale adapted from Lee (Lee 2014).
Time frame: From first dose to 90 days following first dose (up to approximately 90 days)
Percentage of Participants With Neurotoxicity (NT) Adverse Events Grade ≥ 3
NT events have also been reported and may include neurologic symptoms such as altered mental status, aphasia, altered level of consciousness, and seizures or seizure-like activity. Incidence of Grade ≥ 3 NT, defined as an Investigator-identified TEAE considered neurotoxicity related to JCAR017.
Time frame: From first dose to 90 days following first dose (up to approximately 90 days)
Percentage of Participants With Infection Adverse Events Grade ≥ 3
Incidence of treatment-emergent Grade ≥ 3 infections, defined using MedDRA SOC.
Time frame: From first dose to 90 days following first dose (up to approximately 90 days)
Percentage of Participants With Grade ≥ 3 Prolonged Cytopenia at Day 29.
Prolonged cytopenia is defined as the occurrence of Grade ≥ 3 cytopenia not resolved by the Day 29 visit, based on laboratory results of low hemoglobin, absolute neutrophil count decreased, and platelet count decreased. The frequency of subjects experiencing each individual laboratory abnormality and the total number with at least 1 abnormality will be summarized, as will recovery from prolonged cytopenia after Day 29.
Time frame: At Day 29 after first treatment
Number of Participants With Adverse Events
Time frame: From first dose to 90 days following first dose (up to approximately 90 days)
Number of Participants With Clinically Significant Laboratory Abnormalities- Hematology
Time frame: From first dose to up to 41 months
Number of Participants With Clinically Significant Laboratory Abnormalities- Chemistry
Time frame: From first dose to up to 41 months
Number of Participants With Adverse Events Grade ≥ 3
Time frame: From first dose to 90 days following first dose (up to approximately 90 days)
Time to Onset and Time to Resolution of Grade ≥ 3 Cytokine Release Syndrome (CRS)
Time frame: From first dose to up to approximately 41 months
Time to Onset and Time to Resolution of Grade ≥ 3 Neurotoxicity (NT)
Time frame: From first dose to up to approximately 41 months
Number of Participants Administered Tocilizumab and Corticosteroid for Management of Cytokine Release Syndrome (CRS)
Time frame: From first dose to up to approximately 41 months
Number of Participants Administered Tocilizumab and Corticosteroid for Management of Neurotoxicity (NT)
Time frame: From first dose to up to study completion (Approximately 57 Months and 24 days)
Objective Response Rate (ORR)
The Percentage of participants with a best overall response (BOR) of either CR or PR based on the Lugano 2014 criteria. Disease response will be determined according to the "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" Complete response is defined as: 1. Score 1, 2, or 3a with or without residual mass 2. No evidence of FDG-avid disease in marrow Partial Response is defined as: 1. Score 4 or 5a with reduced uptake compared with baseline and residual masses of any size 2. Bone marrow with residual uptake higher than in normal marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). If there are persistent focal changes in marrow in the context of a nodal response, should consider further evaluation with MRI, biopsy, or interval scan.
Time frame: From first dose to up to approximately 41 months
Complete Response Rate (CRR)
The Percentage of participants with a best overall response (BOR) with CR based on the Lugano 2014 criteria. Disease response will be determined according to the "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" Complete response is defined as: 1. Score 1, 2, or 3a with or without residual mass 2. No evidence of FDG-avid disease in marrow
Time frame: From first dose to up to approximately 41 months
Duration of Response (DoR) and Duration of Complete Response (DoCR)
Duration of response (DOR) is defined as the time from the first documentation of response (CR or PR) after JCAR017 infusion to disease progression or death from any cause, whichever occurs first. Duration of response (DOR) if BOR is CR is defined for subjects with a BOR of CR as the time from the first documentation of response (CR or PR) after JCAR017 infusion to earlier of disease progression or death from any cause.
Time frame: From first dose to up to approximately 41 months
Progression Free Survival (PFS)
Progression-free survival is defined as the time from infusion of JCAR017 to progressive disease or death, whichever is earlier. If a subject does not have an event for the PFS analysis, the subject will be censored. Progressive Disease is defined as: 1. Score 4 or 5a with an increase in intensity of uptake from nadir 2. New FDG-avid foci consistent with lymphoma (may need biopsy or repeat scan if uncertain about etiology of foci). 3. Investigator assessed clinical progression
Time frame: From first dose to up to study completion (Approximately 57 Months and 24 days)
Overall Survival (OS)
Overall survival is defined as the time from infusion of JCAR017 to the date of death. For assessment of OS, data from surviving participants will be censored at the last time that the participant is known to be alive. The OS analysis will include all available survival information from the long-term follow-up study if applicable.
Time frame: From first dose to up to study completion (Approximately 57 Months and 24 days)
Area Under the Blood Concentration-time Curve From Time to Zero to 28 Days After Dosing AUC (0-28)
Time frame: 28days after first dose
Maximum Observed Blood Concentration (Cmax)
Time frame: 28days after first dose
Time of Maximum Observed Blood Concentration (Tmax)
Time frame: 28days after first dose
Mean Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A higher scale score represents a higher level of well-being and better ability of daily functioning. Thus, a high score for a functional scale represents a high/healthy level of functioning; a high score for the global health status/HRQoL represents a high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatic problem.
Time frame: From Enrollment to end of follow up, approximately 26 months
Mean Change From Baseline in EuroQol Instrument EQ-5D-5L.
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. The EQ-5D-5L health utility index (HUI) is assessed using the Crosswalk algorithm for France based on the individual responses to the 5 EQ-5D-5L domains ranging from -0.530 to 1.000. The smallest change considered clinically meaningful, is defined as a score difference of 0.08 points.
Time frame: Post Dose Month 24
Number of Intensive Care Unit (ICU) Inpatient Days and Non-ICU Inpatient Days and Reasons for Hospitalization
Length of initial ICU and non-ICU stay from liso-cel administration
Time frame: From first hospitalization to the last. Approximately 31 days
Number of Participants Who Received Transfusions
Number of participants who received transfusions
Time frame: From first dose to end of treatment period approximately 24 months
Number of Participants Requiring Growth Factor Support.
Growth factor support was defined as concomitant administration of FILGRASTIM, TBO FILGRASTIM, PEGFILGRASTIM, FILGRASTIM SNDZ, or FILGRASTIM AAFI.
Time frame: From first dose to end of treatment period approximately 24 months
Number of Participants Requiring Intravenous Immunoglobulin (IVIG) Support
Number of participants requiring intravenous immunoglobulin (IVIG) support
Time frame: From first dose to end of treatment period approximately 24 months
| Milestone | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Started | 104 |
| Completed | 84 |
| Not completed | 20 |
| Withdrew: Disease related complications | 2 |
| Withdrew: No longer meets study criteria | 4 |
| Withdrew: Death | 7 |
| Withdrew: Other reasons | 7 |
| Milestone | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Started | 82 |
| Participants who received ldc and non conforming product | 1 |
| Completed | 35 |
| Not completed | 47 |
| Withdrew: Participant withdrew consent | 8 |
| Withdrew: Death | 33 |
| Withdrew: Other reasons | 6 |
Cytokine release syndrome is characterized by high fever, fatigue, nausea, headache, dyspnea, tachycardia, rigors, hypotension, hypoxia, myalgia/arthralgia, and anorexia. Incidence of Grade ≥ 3 CRS, based on the TEAE with MedDRA PT "Cytokine release syndrome," graded according to the grading scale adapted from Lee (Lee 2014).
| Percentage of participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Percentage of Participants With Cytokine Release Syndrome (CRS) Adverse Events Grade ≥ 3 | 0.0 (0.0 to 4.4) |
NT events have also been reported and may include neurologic symptoms such as altered mental status, aphasia, altered level of consciousness, and seizures or seizure-like activity. Incidence of Grade ≥ 3 NT, defined as an Investigator-identified TEAE considered neurotoxicity related to JCAR017.
| Percentage of participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Percentage of Participants With Neurotoxicity (NT) Adverse Events Grade ≥ 3 | 9.8 (4.3 to 18.3) |
Incidence of treatment-emergent Grade ≥ 3 infections, defined using MedDRA SOC.
| Percentage of participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Percentage of Participants With Infection Adverse Events Grade ≥ 3 | 11.0 (5.1 to 19.8) |
Prolonged cytopenia is defined as the occurrence of Grade ≥ 3 cytopenia not resolved by the Day 29 visit, based on laboratory results of low hemoglobin, absolute neutrophil count decreased, and platelet count decreased. The frequency of subjects experiencing each individual laboratory abnormality and the total number with at least 1 abnormality will be summarized, as will recovery from prolonged cytopenia after Day 29.
| Percentage of participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Percentage of Participants With Grade ≥ 3 Prolonged Cytopenia at Day 29. | 32.9 (22.9 to 44.2) |
| Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Number of Participants With Adverse Events | 82 |
| Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Number of Participants With Clinically Significant Laboratory Abnormalities- Hematology | 0 |
| Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Number of Participants With Clinically Significant Laboratory Abnormalities- Chemistry | 0 |
| Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Number of Participants With Adverse Events Grade ≥ 3 | 61 |
| Days | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Time to Onset | 0 (0 to 0) |
| Time to Resolution | 0 (0 to 0) |
| Days | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Time to Onset | 9.5 (3 to 33) |
| Time to Resolution | 16.5 (5 to 47) |
| Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Tocilizumab Only | 7 |
| Corticosteroid Only | 2 |
| Both Tocilizumab and Corticosteroid | 7 |
| Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Tocilizumab Only | 0 |
| Corticosteroid Only | 12 |
| Both Tocilizumab and Corticosteroid | 1 |
The Percentage of participants with a best overall response (BOR) of either CR or PR based on the Lugano 2014 criteria. Disease response will be determined according to the "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" Complete response is defined as: 1. Score 1, 2, or 3a with or without residual mass 2. No evidence of FDG-avid disease in marrow Partial Response is defined as: 1. Score 4 or 5a with reduced uptake compared with baseline and residual masses of any size 2. Bone marrow with residual uptake higher than in normal marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). If there are persistent focal changes in marrow in the context of a nodal response, should consider further evaluation with MRI, biopsy, or interval scan.
| Percentage of Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Objective Response Rate (ORR) | 80.5 (70.3 to 88.4) |
The Percentage of participants with a best overall response (BOR) with CR based on the Lugano 2014 criteria. Disease response will be determined according to the "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" Complete response is defined as: 1. Score 1, 2, or 3a with or without residual mass 2. No evidence of FDG-avid disease in marrow
| Percentage of Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Complete Response Rate (CRR) | 53.7 (42.3 to 64.7) |
Duration of response (DOR) is defined as the time from the first documentation of response (CR or PR) after JCAR017 infusion to disease progression or death from any cause, whichever occurs first. Duration of response (DOR) if BOR is CR is defined for subjects with a BOR of CR as the time from the first documentation of response (CR or PR) after JCAR017 infusion to earlier of disease progression or death from any cause.
| Months | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| DoR | 14.75 (5.03 to NA) |
| DoCR | NA (16.59 to NA) |
Progression-free survival is defined as the time from infusion of JCAR017 to progressive disease or death, whichever is earlier. If a subject does not have an event for the PFS analysis, the subject will be censored. Progressive Disease is defined as: 1. Score 4 or 5a with an increase in intensity of uptake from nadir 2. New FDG-avid foci consistent with lymphoma (may need biopsy or repeat scan if uncertain about etiology of foci). 3. Investigator assessed clinical progression
| Months | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Progression Free Survival (PFS) | 5.86 (0.7 to 26.7) |
Overall survival is defined as the time from infusion of JCAR017 to the date of death. For assessment of OS, data from surviving participants will be censored at the last time that the participant is known to be alive. The OS analysis will include all available survival information from the long-term follow-up study if applicable.
| Months | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Overall Survival (OS) | 21.88 (1.0 to 50.1) |
| day*copies/μg | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Area Under the Blood Concentration-time Curve From Time to Zero to 28 Days After Dosing AUC (0-28) | 219760.3 ± 216.1 |
| copies/μg | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Maximum Observed Blood Concentration (Cmax) | 24077.8 ± 230.7 |
| days | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Time of Maximum Observed Blood Concentration (Tmax) | 10.0 (7 to 28) |
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A higher scale score represents a higher level of well-being and better ability of daily functioning. Thus, a high score for a functional scale represents a high/healthy level of functioning; a high score for the global health status/HRQoL represents a high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatic problem.
| Scores on a Scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Apptetie Loss | -22.7 ± 23.87 |
| Cognitive Functioning | 1.5 ± 18.48 |
| Constipation | -7.6 ± 27.08 |
| Diarrhea | -3.0 ± 27.04 |
| Dyspnea | 6.1 ± 13.16 |
| Emotional Functioning | 2.7 ± 20.31 |
| Fatigue | -14.6 ± 21.24 |
| Financial Difficulties | -9.1 ± 25.58 |
| Global Health Stuats/QoL | 15.2 ± 21.61 |
| Insomnia | -10.6 ± 27.96 |
| Nausea and Vomiting | -9.8 ± 17.56 |
| Pain | -13.6 ± 26.55 |
| Physical Functioning | 2.4 ± 16.14 |
| Role Functioning | 12.9 ± 23.53 |
| Social Functioning | 17.4 ± 24.92 |
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. The EQ-5D-5L health utility index (HUI) is assessed using the Crosswalk algorithm for France based on the individual responses to the 5 EQ-5D-5L domains ranging from -0.530 to 1.000. The smallest change considered clinically meaningful, is defined as a score difference of 0.08 points.
| Score on a Scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Mean Change From Baseline in EuroQol Instrument EQ-5D-5L. | 0.0 ± 0.13 |
Length of initial ICU and non-ICU stay from liso-cel administration
| days | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Initial ICU Stay | 5.5 (4 to 7) |
| Initial Non-ICU Stay | 15.0 (0 to 31) |
Number of participants who received transfusions
| Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Number of Participants Who Received Transfusions | 43 |
Growth factor support was defined as concomitant administration of FILGRASTIM, TBO FILGRASTIM, PEGFILGRASTIM, FILGRASTIM SNDZ, or FILGRASTIM AAFI.
| Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Number of Participants Requiring Growth Factor Support. | 35 |
Number of participants requiring intravenous immunoglobulin (IVIG) support
| Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Number of Participants Requiring Intravenous Immunoglobulin (IVIG) Support | 12 |
Collected over Participants were assessed for all-cause mortality from their first dose until study completion (up to approximately 57 months and 24 days). SAEs and Other AEs were assessed from first dose to 90 days following first dose (up to approximately 90 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lisocabtagene Maraleucel (JCAR017) | 48/82 (58.5%) | 48/82 (58.5%) | 82/82 (100%) |
| Event | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Cytokine release syndromeImmune system disorders | 24/82 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/82 |
| SepsisInfections and infestations | 5/82 |
| PyrexiaGeneral disorders | 4/82 |
| Cognitive disorderNervous system disorders | 4/82 |
| EncephalopathyNervous system disorders | 4/82 |
| TremorNervous system disorders | 4/82 |
| HeadacheNervous system disorders | 3/82 |
| NeutropeniaBlood and lymphatic system disorders | 2/82 |
| Supraventricular tachycardiaCardiac disorders | 2/82 |
| Event | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 55/82 |
| LeukopeniaBlood and lymphatic system disorders | 36/82 |
| ThrombocytopeniaBlood and lymphatic system disorders | 29/82 |
| AnaemiaBlood and lymphatic system disorders | 28/82 |
| FatigueGeneral disorders | 25/82 |
| NauseaGastrointestinal disorders | 21/82 |
| HeadacheNervous system disorders | 20/82 |
| ConstipationGastrointestinal disorders | 19/82 |
| DiarrhoeaGastrointestinal disorders | 19/82 |
| Decreased appetiteMetabolism and nutrition disorders | 19/82 |
| Age, Continuous(Years) | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Mean | 64.9 ± 11.61 |
| Sex: Female, Male(Participants) | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Female | 38 |
| Male | 66 |
| Ethnicity (NIH/OMB)(Participants) | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Hispanic or Latino | 19 |
| Not Hispanic or Latino | 77 |
| Unknown or Not Reported | 8 |
| Race/Ethnicity, Customized(Participants) | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| White | 88 |
| Other | 7 |
| Unknown | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Nov 2018 to primary completion in Sep 2023, 57 months.
Results were first posted in Dec 2023, 2 months after primary completion.
Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 57 months is above that.
Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisocabtagene maraleucel
Lymphoma, Large B-Cell, Diffuse →
Juno Therapeutics, a Subsidiary of Celgene →